CHELMSFORD, Mass.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that the East of England Ambulance Service NHS Trust has placed orders for more than £1.6 million ($3.0 million USD) of life-saving equipment. The equipment consists of 15 AutoPulse® Non-invasive Cardiac Support Pumps, 120 new ZOLL E Series™ frontline monitor/defibrillators, and 150 AED Pro® automated external defibrillators. East of England Ambulance Service is now the third NHS trust to purchase this range of groundbreaking technology. Approximately one-half of this order shipped during the fourth quarter of fiscal 2006. The balance will ship in the second half of fiscal 2007.
The E Series, a rugged defibrillator designed for emergency-care professionals, is the latest in ZOLL’s range of resuscitation equipment designed to meet the specific clinical requirements and operational demands that East of England paramedics and EMTs face every day. Archie Morson, Head of Clinical Quality and Development, said, “This range of equipment allows our paramedics to provide improved clinical care and treatment. The defibrillators offer our patients the very best in clinical diagnostic tools, and provide our paramedics with parameters specifically designed for pre-hospital challenges. They will enhance the clinical treatment through EtCO2 monitoring, high-quality 12-lead ECG acquisition, and robust telemetry. They also offer seamless equipment integration across the first-responder and paramedic disciplines.”
Mr. Morson added, “Paramedic staff stationed in Cromer, Ipswich, and Peterborough evaluated a number of machines. The staff was impressed with the ZOLL defibrillators, especially their proven EMS reliability and enhanced diagnostic tools. We believe that ZOLL’s range of resuscitation equipment will help improve our patient treatment and save more lives.”
Since East of England Ambulance Service is one of the foremost providers of pre-hospital thrombolytics (i.e., “clot-busting” drugs that dissolve blood clots), it is essential that they have the best equipment available to provide rapid and clear identification of heart attack patients. This empowers each paramedic to provide the best possible care and treatment either through immediate “clot-busting” drug therapy and/or via robust ECG telemetry. EtCO2 is widely regarded as a standard of care, and this critical monitoring parameter will help to further improve patient care and treatment.
Mr. Morson also noted, “We are very excited about the AutoPulse, which is designed to provide blood flow during sudden cardiac arrest. It can move more blood than can be done with human hands during manual CPR. It also offers the benefit of freeing up paramedics and technicians to focus on other life-saving interventions. Published data concerning its use from other ambulances services around the world drew our attention to the device, and we want to make sure we do everything possible to save someone’s life when they need us most.”
Richard A. Packer, ZOLL’s President and Chief Executive Officer, commented, “We are pleased to have the opportunity to broaden our presence in the UK pre-hospital market. East of England Ambulance, which was formed through the recent merger of three UK ambulance services, serves more than 5 million people in a coverage area of more than 7,400 square miles. We appreciate that its paramedics chose ZOLL equipment to meet their clinical requirements and the operational demands that they face every day.”
About ZOLL Medical Corporation
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation (with ZOLL’s See-Thru CPR™ and Real CPR Help™ technologies), ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.
ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. For more information, visit www.zoll.com or call +1 (978) 421-9655.
Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the resuscitation business; acceptance of its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-Q, which was filed with the SEC on August 11, 2006.
©2006 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. E Series is a trademark of ZOLL Medical Corporation. AED Pro, AutoPulse, and ZOLL are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.